Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613Co-Development and Marketing Agreement • August 30th, 2017
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; “Ono”) and Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) announced that they have reached a definitive agreement (“the agreement”) related to co-development and marketing collaboration on SI-613 in Japan under development by Seikagaku for the treatment of osteoarthritis. The agreement is based on the basic agreement reached on May 12, 2017.
EXHIBIT 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED....Co-Development and Marketing Agreement • February 9th, 2000 • Noosh Inc • Services-business services, nec • California
EXHIBIT 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED....Co-Development and Marketing Agreement • March 24th, 2000 • Noosh Inc • Services-business services, nec
